US3360503A
(en)
*
|
1963-04-09 |
1967-12-26 |
Du Pont |
Process for preparing poly(alpha, alpha-disubstituted beta-lactams)
|
DE2048080C3
(de)
*
|
1970-09-30 |
1979-11-29 |
Basf Ag, 6700 Ludwigshafen |
Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen
|
EP0180398A1
(en)
*
|
1984-10-26 |
1986-05-07 |
The Regents Of The University Of California |
Synthesis of beta-lactam
|
CA1305177C
(en)
|
1987-06-30 |
1992-07-14 |
Yasufumi Ohfune |
Carboxycyclopropylglycine and process for producing the same
|
US4904681A
(en)
|
1987-12-01 |
1990-02-27 |
G. D. Searle & Co. |
D-cycloserine and its prodrugs as cognitive enhancers
|
EP0360390A1
(en)
|
1988-07-25 |
1990-03-28 |
Glaxo Group Limited |
Spirolactam derivatives
|
US5061721A
(en)
|
1989-03-15 |
1991-10-29 |
G. D. Searle & Co. |
Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
CA2058975C
(en)
|
1990-10-30 |
2000-06-06 |
Shuichi Kasai |
Antiinflammatory gel preparation
|
US5168103A
(en)
|
1991-01-22 |
1992-12-01 |
American Home Products Corporation |
[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
|
CA2058223A1
(en)
*
|
1991-12-20 |
1993-06-21 |
Bing-Yan Zhu |
Process for preparing beta-lactams
|
FR2692268B1
(fr)
|
1992-06-15 |
1994-08-19 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
|
SE9301667D0
(sv)
|
1993-05-14 |
1993-05-14 |
Kabi Pharmacia Ab |
New use
|
US5523323A
(en)
|
1993-09-14 |
1996-06-04 |
Maccecchini; Maria-Luisa |
Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
|
US5605911A
(en)
|
1995-01-31 |
1997-02-25 |
Washington University |
Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
US5763393A
(en)
|
1996-05-17 |
1998-06-09 |
Neurotherapeutics L.P. |
Neuroactive peptides
|
WO1997046578A1
(en)
|
1996-06-07 |
1997-12-11 |
Zeneca Limited |
Peptide derivatives
|
JP2000503860A
(ja)
|
1996-08-02 |
2000-04-04 |
ザイモジェネティクス,インコーポレイティド |
精巣―特異的インシュリン同族体ポリペプチド
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
JP3955345B2
(ja)
|
1996-09-27 |
2007-08-08 |
サントリー株式会社 |
新規アミノ酸ダイジハーベイン
|
WO1999024584A1
(en)
|
1997-11-12 |
1999-05-20 |
Neurotherapeutics |
Methods for the detection and treatment of disease using a glycosyltransferase
|
US5952389A
(en)
|
1998-01-13 |
1999-09-14 |
Synchroneuron |
Methods of treating tardive dyskinesia and other movement disorders
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
US6274314B1
(en)
|
1998-04-02 |
2001-08-14 |
Nyxis Neurotherapies, Inc. |
Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
|
US6197820B1
(en)
|
1998-04-06 |
2001-03-06 |
Uab Research Foundation |
Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
|
US6025471A
(en)
|
1998-06-03 |
2000-02-15 |
Deghenghi; Romano |
Diazaspiro, azepino and azabicyclo therapeutic peptides
|
WO2000027790A1
(en)
|
1998-11-11 |
2000-05-18 |
Smithkline Beecham P.L.C. |
Mutilin compounds
|
WO2000028090A2
(en)
|
1998-11-12 |
2000-05-18 |
Nyxis, Inc. |
Diagnostic assay for cancer
|
US20030064921A1
(en)
|
1999-10-27 |
2003-04-03 |
The Regents Of The University Of California |
Methods and compounds for modulating melanocortin receptor ligand binding and activity
|
WO2001036685A2
(en)
|
1999-11-17 |
2001-05-25 |
Nyxis Neurotherapies, Inc. |
Differential gene expression in cancer
|
CA2398250A1
(en)
|
2000-02-01 |
2001-08-09 |
Agy Therapeutics, Inc. |
Interaction of nmda receptor with protein tyrosine phosphatase
|
JP2001261679A
(ja)
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
|
WO2001096606A2
(en)
|
2000-06-14 |
2001-12-20 |
Nyxis Neurotherapies, Inc. |
Identification of genes and compounds for treatment of cancer
|
CA2413974A1
(en)
|
2000-06-22 |
2001-12-27 |
Nyxis Neurotherapies, Inc. |
Neuroactive peptides for treatment of hypoxia and related conditions
|
GB0018272D0
(en)
|
2000-07-25 |
2000-09-13 |
Vernalis Research Limited |
Chemical compounds IV
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
EP1186303A3
(en)
|
2000-09-06 |
2003-12-10 |
Pfizer Products Inc. |
Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
US20020142287A1
(en)
|
2000-12-14 |
2002-10-03 |
Hirotaka Yamamoto |
High throughput assay to detect inhibitors of the map kinase pathway
|
US20030065138A1
(en)
|
2001-03-07 |
2003-04-03 |
University Of Utah Research Foundation |
Linear gamma-carboxyglutamate rich conotoxins
|
AU2002255705A1
(en)
|
2001-03-12 |
2002-09-24 |
Nyxis Neurotherapies, Inc |
Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
|
WO2003010540A1
(en)
|
2001-07-25 |
2003-02-06 |
Nyxis Neurotherapies, Inc. |
Method of identifying nmda-related agent
|
WO2004005293A2
(en)
|
2002-07-05 |
2004-01-15 |
Targacept, Inc. |
N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
WO2004094371A2
(en)
|
2003-04-17 |
2004-11-04 |
Merck & Co., Inc. |
Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
|
WO2005007656A1
(en)
|
2003-07-18 |
2005-01-27 |
Virochem Pharma Inc. |
Spiro compounds and methods for the modulation of chemokine receptor activity
|
EP1660634A4
(en)
|
2003-08-08 |
2009-02-18 |
Burnham Inst |
P16-mediated regulation of NMDA receptors
|
US7662856B2
(en)
|
2003-08-29 |
2010-02-16 |
The University Of Houston System |
Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
|
GB0323204D0
(en)
|
2003-10-03 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
JPWO2005047286A1
(ja)
|
2003-11-13 |
2007-05-31 |
小野薬品工業株式会社 |
スピロ複素環化合物
|
EP1720873B1
(en)
|
2004-01-08 |
2011-02-23 |
F. Hoffmann-La Roche AG |
Diaza-spiropiperidine derivatives
|
WO2006034196A1
(en)
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions for enhancing memory and methods therefor
|
CN101090902B
(zh)
|
2004-10-13 |
2013-05-29 |
默沙东公司 |
Cgrp受体拮抗剂
|
DK2030622T3
(da)
|
2005-03-24 |
2011-05-02 |
Univ Emory |
Doseringsangivelse af progesteron i behandlingen af en traumatisk hjerneskade
|
US7951912B2
(en)
|
2005-08-26 |
2011-05-31 |
Wisconsin Alumni Research Foundation |
Poly-β-peptides from functionalized β-lactam monomers and antibacterial compositions containing same
|
AR059224A1
(es)
|
2006-01-31 |
2008-03-19 |
Jerini Ag |
Compuestos para la inhibicion de integrinas y uso de estas
|
WO2007103719A2
(en)
|
2006-03-03 |
2007-09-13 |
Incyte Corporation |
MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
|
MX2009002921A
(es)
|
2006-09-15 |
2009-04-01 |
Schering Corp |
Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
|
JP2008188285A
(ja)
|
2007-02-06 |
2008-08-21 |
Bridgestone Corp |
バックパッド及び車両用シート
|
JP2010522194A
(ja)
|
2007-03-20 |
2010-07-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害薬として有用なアミノピリミジン
|
CN101066945B
(zh)
|
2007-05-25 |
2010-05-19 |
中国科学院上海有机化学研究所 |
一种合成3-位取代内酰胺类化合物的方法
|
CN101125817B
(zh)
|
2007-08-03 |
2011-09-14 |
中国科学院上海有机化学研究所 |
一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
|
US20090054392A1
(en)
|
2007-08-20 |
2009-02-26 |
Wyeth |
Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
|
WO2009039390A2
(en)
|
2007-09-20 |
2009-03-26 |
Naurex Inc. |
The development of glycobiology-based therapeutics for the treatment of brain tumors
|
CA2716375C
(en)
|
2008-02-20 |
2018-05-29 |
The Children's Hospital Of Philadelphia |
Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
|
US20110105480A1
(en)
|
2008-06-24 |
2011-05-05 |
Keith Freehauf |
Pharmaceutical transdermal compositions and method for treating inflammation in cattle
|
WO2009156396A1
(en)
|
2008-06-27 |
2009-12-30 |
Neurosearch A/S |
Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
|
BRPI0916609A2
(pt)
|
2008-08-07 |
2015-08-04 |
Hoffmann La Roche |
Processo para a preparação de um macrociclo
|
GB0814991D0
(en)
*
|
2008-08-15 |
2008-09-24 |
Glaxo Group Ltd |
Compounds
|
KR101769999B1
(ko)
|
2008-09-18 |
2017-08-21 |
노오쓰웨스턴 유니버시티 |
Nmda 수용체 조절제 및 그의 용도
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
DE102009001460B4
(de)
|
2009-03-11 |
2010-12-02 |
Zf Friedrichshafen Ag |
Ölbehälter
|
US8329904B2
(en)
|
2009-05-12 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
US20120178695A1
(en)
|
2009-07-02 |
2012-07-12 |
Joseph Moskal |
Methods of treating neuropathic pain
|
WO2011044089A2
(en)
|
2009-10-05 |
2011-04-14 |
Joseph Moskal |
Methods of treating depression and other related diseases
|
US8951968B2
(en)
|
2009-10-05 |
2015-02-10 |
Northwestern University |
Methods of treating depression and other related diseases
|
US8871208B2
(en)
|
2009-12-04 |
2014-10-28 |
Abbvie Inc. |
11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
|
AR079553A1
(es)
|
2009-12-21 |
2012-02-01 |
Novartis Ag |
Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
|
SG10201811584RA
(en)
|
2010-02-11 |
2019-01-30 |
Univ Northwestern |
Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
US8097634B2
(en)
|
2010-04-15 |
2012-01-17 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
CN102267995A
(zh)
|
2010-06-04 |
2011-12-07 |
艾琪康医药科技(上海)有限公司 |
一种制备二氮杂螺环化合物的方法
|
AR082633A1
(es)
|
2010-08-12 |
2012-12-19 |
Tetraphase Pharmaceuticals Inc |
Analogos de tetraciclina
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
WO2012116217A1
(en)
|
2011-02-25 |
2012-08-30 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
EA023876B1
(ru)
|
2011-03-14 |
2016-07-29 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бензодиоксановые ингибиторы продуцирования лейкотриена
|
KR101309156B1
(ko)
*
|
2011-03-24 |
2013-09-17 |
삼성에스디아이 주식회사 |
리튬 이차 전지용 전해액 및 이를 포함하는 리튬 이차 전지
|
AU2012249397B2
(en)
|
2011-04-27 |
2017-03-30 |
Northwestern University |
Methods of treating Alzheimer's disease, Huntington's disease, autism, or other disorders
|
WO2013001448A1
(en)
|
2011-06-27 |
2013-01-03 |
Koninklijke Philips Electronics N.V. |
Ultrasound transducer assembly and method of manufacturing the same
|
EP2734299A4
(en)
|
2011-07-18 |
2016-05-11 |
Univ Alberta |
CATALYSTS AND METHODS FOR HYDROGENATION OF AMIDES
|
CA2881991C
(en)
|
2011-07-27 |
2016-10-25 |
Astrazeneca Ab |
Substituted 3-chloro-n-[3-(pyrimidin-2-ylamino)phenyl]propanamide compound, and salts thereof
|
WO2013091507A1
(zh)
|
2011-12-20 |
2013-06-27 |
Qian Wei |
杂环胺基烷氧基取代的喹唑啉衍生物及其用途
|
AR092031A1
(es)
|
2012-07-26 |
2015-03-18 |
Merck Sharp & Dohme |
Inhibidores del canal de potasio medular externo renal
|
CN102936216B
(zh)
|
2012-12-05 |
2015-03-04 |
南京药石药物研发有限公司 |
7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
|
CA2899010A1
(en)
|
2013-01-29 |
2014-08-07 |
Naurex, Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
EA032153B1
(ru)
|
2013-01-29 |
2019-04-30 |
Аптиникс Инк. |
Спиролактамные модуляторы nmda-рецептора и их применение
|
BR112015018094A2
(pt)
*
|
2013-01-29 |
2017-07-18 |
Naurex Inc |
moduladores de receptor nmda de espiro-lactama e usos dos mesmos
|
DK2951183T3
(da)
|
2013-01-29 |
2019-06-03 |
Aptinyx Inc |
Spiro-lactam-nmda-receptormodulatorer og anvendelser heraf
|
BR112015018092A2
(pt)
|
2013-01-29 |
2017-07-18 |
Naurex Inc |
moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
|
CN103171641B
(zh)
|
2013-03-19 |
2015-07-15 |
浙江大学 |
具备轮动功能的弹跳机器人
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
TWI651310B
(zh)
*
|
2014-02-20 |
2019-02-21 |
日商日本煙草產業股份有限公司 |
三化合物及其醫藥用途
|
GB2528480A
(en)
|
2014-07-23 |
2016-01-27 |
Givaudan Sa |
Improvements in or relating to organic compounds
|
GB201416346D0
(en)
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
WO2017201285A1
(en)
|
2016-05-19 |
2017-11-23 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
MX2018014202A
(es)
|
2016-05-19 |
2019-06-20 |
Aptinyx Inc |
Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
|
CN109937204B
(zh)
|
2016-08-01 |
2022-11-25 |
阿普廷伊克斯股份有限公司 |
螺-内酰胺nmda受体调节剂及其用途
|
AU2017306136B2
(en)
|
2016-08-01 |
2021-10-21 |
Aptinyx Inc. |
Spiro-lactam NMDA receptor modulators and uses thereof
|
CN109843889B
(zh)
|
2016-08-01 |
2022-03-15 |
阿普廷伊克斯股份有限公司 |
螺-内酰胺nmda调节剂和使用其的方法
|
PE20190502A1
(es)
|
2016-08-01 |
2019-04-10 |
Aptinyx Inc |
Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
|
PE20190504A1
(es)
|
2016-08-01 |
2019-04-10 |
Aptinyx Inc |
Moduladores del receptor nmda espiro-lactam y uso de los mismos
|
CA3089559A1
(en)
|
2018-01-31 |
2019-08-08 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
AU2019215058A1
(en)
|
2018-01-31 |
2020-09-17 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
US12012413B2
(en)
|
2019-11-11 |
2024-06-18 |
Tenacia Biotechnology (Hong Kong) Co., Limited |
Methods of treating painful diabetic peripheral neuropathy
|
US20210308101A1
(en)
|
2019-11-11 |
2021-10-07 |
Aptinyx Inc. |
Methods of treating fibromyalgia
|
KR20220110251A
(ko)
|
2019-12-04 |
2022-08-05 |
앱티닉스 인크. |
신경변성 질환과 연관된 인지 장애를 치료하는 방법
|